Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry
Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry
复制标题
DOI：
10.1136/ard.2009.124446
复制
发表时间：
2010-11-01
影响因子：
27.4
通讯作者：
Hetland, Merete Lund
中科院分区：
文献类型：
--
作者：
Glintborg, Bente;Ostergaard, Mikkel;Hetland, Merete Lund
目的 使用丹麦全国风湿病数据库 (DANBIO) 的前瞻性注册数据来描述接受肿瘤坏死因子 a (TNF α) 抑制剂首次治疗系列的强直性脊柱炎 (AS) 患者的疾病活动度、临床反应、治疗持续时间和药物生存预测因子（即个体患者维持治疗的天数）和临床反应。方法 在 DANBIO 中确定了 842 名未使用 TNFa 抑制剂的 AS 患者。研究了临床反应、药物存活及其预测因素。 “临床反应”的定义是 6 个月内巴斯强直性脊柱炎疾病活动指数 (BASDAI) 与基线相比降低 50% 或 20 mm。达到 BASDAI 14 mg/l 和低视觉模拟量表疲劳（Cox 回归分析）。年龄、TNFa 抑制剂和甲氨蝶呤的使用并不显着。 CRP > 14 mg/l、基线时较低的 BASFI 和较年轻的年龄与临床反应和 BASDAI 的实现相关
Objectives To use prospectively registered data from the Danish nationwide rheumatological database (DANBIO) to describe disease activity, clinical response, treatment duration and predictors of drug survival (ie, number of days individual patients maintained treatment) and clinical response among patients with ankylosing spondylitis (AS) receiving their first treatment series with a tumour necrosis factor a (TNF alpha) inhibitor.Methods 842 TNFa inhibitor naive patients with AS were identified in DANBIO. Clinical response, drug survival and predictors thereof were investigated. 'Clinical response' was defined as a 50% or 20 mm reduction in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) within 6 months compared with baseline. Achievement of a BASDAI 14 mg/l and low visual analogue scale fatigue (Cox regression analysis). Age, TNFa inhibitor and methotrexate use were insignificant. CRP > 14 mg/l, lower BASFI and younger age at baseline was associated with clinical response and achievement of a BASDAI